Tag Archives: MTC

DiA Imaging Analysis Partners with SonoScape Medical Corporation to Deliver Cardiac Ultrasound AI solutions


BE’ER SHEVA, Israel, and SHENZHEN, China , May 11, 2021DiA Imaging Analysis Ltd. (DiA), a leading provider of AI-powered ultrasound analysis solutions today announced that it has partnered with SonoScape Medical Corporation  (300633.SZ), a leading developer and manufacturer of ultrasound systems. As part of the partnership, SonoScape’s ultrasound devices will provide DiA’s ultrasound artificial intelligence analysis solutions aiming to reduce the variability associated with manual or visual analysis, and increase efficiency and accuracy throughout the analysis process.

A recent survey indicated that 85% of ultrasound users said that AI saved their practice time and 69% reported that it saved costs. By providing automated ultrasound AI solutions, this partnership fills the growing need for objective and accurate analysis in this booming market where ultrasound analysis is often done in a subjective and time-consuming method – by visual or manual estimations.

"SonoScape is committed to delivering outstanding services to its ultrasound users to help increase their efficiency," said Dr. Nai Zhang Feng, General Manager of Ultrasound Division at SonoScape. "By joining hands with DiA, we will enhance our users’ capabilities with the most innovative technology of cardiac ultrasound AI tools."

DiA’s FDA cleared and CE marked AI-based cardiac solutions, LVivo Toolbox™, were developed by a proprietary technology that imitates the way the human eye detects borders and identifies motion, therefore, allowing ultrasound users with various levels of experience automatically analyze and identify clinical abnormalities that are otherwise difficult to find visually.

"We are thrilled to partner with SonoScape to empower their users with our most advanced ultrasound AI solutions," said Hila Goldman – Aslan, CEO and Co-Founder of DiA Imaging Analysis. "Combining SonoScape’s ultrasound capacities with DiA’s AI technology is another great step forward to make the analysis of ultrasound images smarter and accessible to all."

About DiA Imaging Analysis

DiA Imaging Analysis is a leading provider of AI-powered ultrasound analysis solutions that make the use and analysis of ultrasound images smarter, faster and accessible to all. The company’s FDA cleared and CE marked LVivo™ product line for cardiac and abdominal auto analysis allow clinicians with various levels of ultrasound experience to use and analyze ultrasound images on their ultrasound devices or healthcare IT systems with increased speed, efficiency and accuracy. DiA currently serves thousands of end users worldwide. 
For additional information, please visit www.dia-analysis.com .

About SonoScape

SonoScape Medical Corp. manufactures medical equipment. The Company develops, produces, and sells ultrasound diagnostic systems, transducers, and other medical equipment products. SonoScape Medical serves customers worldwide.

Founded in 2002 in Shenzhen, China, SonoScape has committed itself to "Caring for life through innovation" by providing ultrasound and endoscopy solutions and delivering first-rate services. It now has seven R&D centers in Shenzhen, Shanghai, Harbin, Wuhan, Tokyo, Silicon Valley and Seattle. Ranked as the top 10 ultrasound brands globally, SonoScape invests heavily into R&D annually, with more advanced products to be introduced into the pipeline.

Contact:
Tal Sacharov
VP Marketing
DiA Imaging Analysis
tal.sacharov@dia-analysis.com  
www.dia-analysis.com 

Logo – https://techent.tv/wp-content/uploads/2021/05/dia-imaging-analysis-partners-with-sonoscape-medical-corporation-to-deliver-cardiac-ultrasound-ai-solutions.jpg  

 

 

Related Links :

http://www.dia-analysis.com

Essence Group Launches New WeR@Home+ Smart Home Security Solution

Leading Security Companies Begin Piloting New LTE-enabled Smart Home Solution in Europe

HERZLIYA, Israel, May 6, 2021Essence Group, a leading provider of IoT solutions for the global security and care markets, today announced the launch of WeR@Home+, a next generation security and home management platform. Essence is partnering with European security services providers, including Securitas Direct Switzerland, to pilot the new offering. 

Essence Group Launches New WeR@Home+ Smart Home Security Solution
Essence Group Launches New WeR@Home+ Smart Home Security Solution

WeR@Home+ leverages state-of-the-art IoT technology to expand Essence Group’s existing WeR@Home smart home management offering, including connectivity to LTE networks, a new family of connected security devices, and a rich set of reporting and analytics tools for service providers.

"WeR@Home+ represents our commitment to the mass deployment of smart living solutions that provide peace-of-mind to consumers, enabling them to simply and affordably manage their connected homes remotely, from anywhere and at any time," said Hagai Enoch, COO and head of Essence Group’s security division. "Providing a comprehensive smart home management system that is fully expandable and modular for any home environment, with self-installation and remote maintenance and configuration, we enable service providers across a range of industries – including telecommunications, insurance and real estate – to offer an array of value-added services to meet their customers’ specific needs while benefitting from increased ROI and more flexible business models."

WeR@Home+ boasts a range of new capabilities, including an updated central hub with multiple connectivity options. The new hub includes 4G LTE, in addition to Wi-Fi connectivity, and an extended battery backup to ensure the system is always connected. The high definition, battery-operated video camera is the first in the industry to provide HD video over secure radio frequency, connected locally to the hub. This offers highly secure enhanced video verification and unlimited video storage with an extended battery life of up to five years.

The highlight of the platform comprises the S5 Family of multi-functional detectors, featuring a magnetic door/window sensor, a motion sensor with multi-zone spherical lenses for enhanced coverage, a curtain sensor, and a multi-function button that can be programmed to perform a variety of security and smart home actions. Upgraded cloud capabilities provide unprecedented stability and flexibility for providers, including an interactive and fully customizable smartphone app and administration center, with enhanced reporting and analytics capabilities, enabling them to customize and deploy solutions tailored to customer needs.

"Securitas Direct Switzerland has enjoyed a long and fruitful relationship with Essence Group, our valued partner that has played an integral role in us becoming Switzerland’s leading security solutions provider," said Christian Chenaux, CEO Securitas Direct Switzerland. "We are very pleased to begin this pilot with the WeR@Home+ that provides innovation and the most flexible solution through which we can protect our customers from constantly evolving security threats by enabling them to seamlessly manage their home management and security protocols."

WeR@Home+ is an integral aspect of the realization of the Peace of Mind concept, recently introduced by Essence Group and intended to provide users with a better life experience and  close the gap between their limited resources and the increasing need for safety.

About Essence Group

Essence Group is a global technology leader with a mission to develop and deploy innovative, cloud-based, end-to-end security and healthcare solutions, underpinned by supporting services, that provide peace of mind to users. For over a quarter of a century, Essence has challenged convention by making care and safety both accessible and affordable. With over 70 million connected devices deployed worldwide, Essence helps people to live safer and more independent lives.

For more information: https://www.essence-grp.com/

Follow Essence Group on LinkedInTwitter and Facebook

Media Contact:

Finn Partners for Essence Group
Danny Sudwarts
Danny.sudwarts@finnpartners.com 
(+1) 469-297-2515

Photo: https://techent.tv/wp-content/uploads/2021/05/essence-group-launches-new-werhome-smart-home-security-solution.jpg

FDA Grants Donisi De Novo Clearance for Innovative Contact-Free Multiparameter Health Sensing Solution

TEL AVIV, Israel, May 5, 2021 — The U.S. Food and Drug Administration (FDA) has granted Donisi‘s revolutionary contact-free multiparameter measurement system de novo clearance, making Donisi the first to bring this innovative technology to the medical market.

Contact-Free Health Measurement and Decision Support. Donisi: Changing Lives Without Changing Lifestyles
Contact-Free Health Measurement and Decision Support. Donisi: Changing Lives Without Changing Lifestyles

In addition to the de novo clearance, the ingenuity of Donisi’s groundbreaking system was recently recognized via the publication of their clinical validation study in the Journal of Medical Engineering & Technology and winning first place in the MEDinISRAEL OpenMED Innovation Competition.

"I’m really proud of our team; we developed a medical device that can change the lives of millions of people. Our novel technology is now recognized and cleared by FDA which is a great accomplishment," said Donisi CEO, Yair Brosh.

Backed by 26 granted patents, the system applies a combination of proprietary optics, algorithms, and artificial intelligence to remotely detect and analyze surface-level micro-vibrations caused by the workings of internal organs such as heart and lungs.

Clinical results demonstrate Donisi’s technology maintains medical grade accuracy for people with different medical and physical conditions (physique, skin tone, etc.), without needing to remove clothing or connect the patient to wires or patches.

The company continues to develop its system, building ground-breaking solutions to measure and detect additional cardiopulmonary parameters, such as pulmonary congestion, in collaboration with the Cardiovascular Research Center at the Tel Aviv Sourasky Medical Center. Donisi has already undergone the FDA Presubmission process for the identification of atrial fibrillation (AFib) and plans for additional submissions.

"Having been with the company since its first year, I am awed and inspired to be part of the team that is bringing this amazing futuristic technology to life," said Donisi Chief Medical Officer Dr. Sagi Polani. "This is an exciting step in our path to fulfilling our mission of changing lives without changing lifestyles. As we move forward, I can envision how our medical device will bridge the continuum of care from hospital to home, impacting lives and health," he continued.

"Chartered Group’s investment in Donisi Health indicates our belief in its development of the innovative optical sensing system that would contribute to resolve various challenges in the healthcare market including the silver tsunami and shift from hospital care to home care," said Eyal Agmoni, Chairman of Chartered Group Technology Division, Donisi’s lead investor, and Managing General Partner of Japan Israel High Tech Ventures 2. "The medical market’s response to this development has been extremely enthusiastic and we are excited with the progress made by such a dedicated team of experts."

For more information or to request an interview, please reach out to Donisi Health

 

 

Cleveland Clinic, Lifebanc and Transplant Connect Develop Automated Donor Referral Process

New system streamlines organ donation process, helping to save, heal more lives through donation, transplantation

CLEVELAND, May 4, 2021 — Cleveland Clinic, Lifebanc and Transplant Connect have designed and launched a fully automated donor referral system to streamline the process for hospital staff identifying and evaluating potential organ, tissue and eye donors.


The new process was launched successfully throughout the Cleveland Clinic health system in northeast Ohio in February 2021, following a successful pilot at Cleveland Clinic main campus and Cleveland Clinic Fairview Hospital in 2020. To implement a donor referral process that would work with each of the organization’s platforms, Cleveland Clinic collaborated with Lifebanc, the non-profit organ procurement organization (OPO) for northeast Ohio, and Transplant Connect, a medical software company specializing in donation-transplant software.

One person’s donation can save the lives of up to eight people and enhance the lives of 50 more. The Centers for Medicare & Medicaid Services mandates that every U.S. hospital refer all deaths and imminent deaths to its designated OPO in a timely manner.  When using the existing manual process, which is labor-intensive and time-consuming, hospital staff must identify each potential donor, place a call to notify the OPO and communicate relevant information to allow the donation evaluation to proceed.

"Our clinical and technical caregivers at Cleveland Clinic are continuously working to make improvements to identify candidates for organ donation," said Brent Hicks, senior director of digital and clinical health at Cleveland Clinic. "This resulted in significant workflow and time-saving improvements but still required a lengthy phone call to the OPO. With the new process, a phone call is no longer required. The entire donor referral process is now automated and in use in all of our northeast Ohio locations."

A Cleveland Clinic team of nurses, end-of-life care professionals, and technology experts worked together to automate the internal process while maintaining quality, privacy, and patient safety. The project came to fruition with support from a Cleveland Clinic Caregiver Catalyst Grant that rewards with funds the innovation and initiative of Cleveland Clinic caregivers.

"We pride ourselves on providing high-quality, safe care, and keep looking for ways to innovate," said Meredith Foxx, executive chief nursing officer at Cleveland Clinic. "Working closely with Lifebanc and Transplant Connect, we made improvements to our organ-donation process to benefit patient care, which translates into our nurses spending more time at the bedside with the patient and their family." 

Transplant Connect’s electronic medical record software, known as iTransplant, is used by Lifebanc and most other OPOs in the United States. It facilitates nearly 75% of U.S. organ transplants from deceased donation.  Its automated donor referral interface, known as iReferral, is currently in nationwide rollout with many hospitals and OPOs.  The iReferral interface allows for donor referrals to be sent automatically, immediately and securely from the hospital’s electronic medical records system to the OPO’s iTransplant system.

"This iReferral launch with Cleveland Clinic and Lifebanc is the largest deployment of automated donor referral technology to date," said John Piano, founder and chief executive officer at Transplant Connect and inventor of the automated donor referral.

"We are honored to have worked through this process with Transplant Connect and Cleveland Clinic," said Lifebanc’s Chief Executive Officer Gordon Bowen. "By streamlining the organ donation referral process, the results will lead to more donors and more organs for those waiting for a life-saving gift."

ABOUT CLEVELAND CLINIC: Cleveland Clinic – now in its centennial year – is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual "America’s Best Hospitals" survey. Among Cleveland Clinic’s 70,800 employees worldwide are more than 4,660 salaried physicians and researchers, and 18,500 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,500-bed health system that includes a 173-acre main campus near downtown Cleveland, 19 hospitals, more than 220 outpatient facilities, and locations in southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2020, there were 8.7 million total outpatient visits, 273,000 hospital admissions and observations, and 217,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.

ABOUT LIFEBANC: Lifebanc is Northeast Ohio’s non-profit organ, eye and tissue recovery organization with a mission to save and heal lives. The organization serves over 4 million people and works with 80 hospitals in a 20-county area. Lifebanc facilitates the organ, eye and tissue recovery and donation processes, provides extensive care and support services to donor families, as well as coordinates community outreach and education programs to encourage registration on the Ohio Donor Registry. For more information on Lifebanc or to register as an organ, eye and tissue donor visit www.lifebanc.org

ABOUT TRANSPLANT CONNECT:  Transplant Connect is a socially-conscious medical software enterprise based in Los Angeles. Its iTransplant Donation-Transplant Ecosystem Software Platform is used to facilitate nearly 75% of all deceased donation in the U.S. as well as across a number of other countries and is relied upon every day by many thousands of medical professionals at hospitals, OPOs, transplant centers, tissue banks, eye banks, transport companies and other organizations.  Integrated with its interoperable iTransplant Platform, the company’s iReferral Hospital EMR Interface technology is in wide U.S. rollout and is disrupting and replacing the inefficient and time-consuming manual donor referral process between hospitals and OPOs.  www.transplantconnect.com

ABOUT ORGAN, TISSUE AND EYE DONATION:  Despite the increase in organ, eye and tissue donors there remains a critical organ shortage in the United States. There are currently 118,195 people waiting for a life-saving organ transplant across the country. There are 1,655 people waiting in Northeast Ohio alone. In 2020, 360 people in Northeast Ohio either died waiting for an organ or became too sick to transplant.

The best chance those still waiting have at receiving the life-saving transplant they need is by increasing the number of people who register their wishes to be an organ, eye and tissue donor. In 2020, over 47,712 people in Northeast Ohio registered for the first time on the Ohio Donor Registry.

To learn more about what it means to be an organ, eye and tissue donor and to register online, please click herehttps://www.lifebanc.org/how-to-help/register-as-a-donor/

 

Related Links :

http://www.transplantconnect.com

Ascensia Rolls Out The On@Pro Online Educational Platform for Healthcare Professionals in Collaboration With the Tumaini Institute


BASEL, Switzerland, April 28, 2021 — Ascensia Diabetes Care, a leading global diabetes care company, has announced today that it has rolled out an online educational platform for continuous personal learning aimed at healthcare professionals working with people with diabetes. The On@Pro tool, which was originally piloted in September 2020, has been developed in partnership with the TUMAINI Institute in Germany, through a collaboration with Professor Peter Schwarz, a globally renowned diabetes expert.

Ascensia Diabetes Care has rolled out an online educational platform for continuous personal learning aimed at healthcare professionals working with people with diabetes
Ascensia Diabetes Care has rolled out an online educational platform for continuous personal learning aimed at healthcare professionals working with people with diabetes

On@Pro is currently available in 13 countries, including the Middle East (Saudi Arabia, Bahrain, Kuwait, Lebanon and the UAE), South Africa, Egypt, India, Malaysia, Singapore, China Hong Kong, the Philippines and Nepal, and there are plans to add additional markets over the course of 2021. It can be accessed via Android, Microsoft and iOS enabled devices such as smartphones, tablets and PCs, through a personal access code which can be obtained from Ascensia in countries where the tool is currently being offered. Access is free of charge to ensure access for as many healthcare professionals as possible.

The platform currently offers a total of 32 modules[1], all in English language, relating to various aspects of diabetes care and management. Each module includes a 3-4 minute introductory video, a set of educational slides and an assessment tool that enables the user to receive certification[2]. In certain markets, including South Africa, Saudi Arabia, Lebanon and UAE, the tool has been accredited and completion of modules can lead to CME (Continuing Medical Education) credits.

Rob Schumm, President at Ascensia Diabetes Care commented: "Through our conversations with healthcare professionals, we became aware of a strong desire for a more comprehensive education platform in diabetes. As part of our ongoing commitment to the diabetes community, one of our priorities is to provide free educational resources to healthcare professionals that can build a greater understanding of diabetes and its management. We believe this will equip HCPs, including GPs, nurses and pharmacists, with the knowledge needed to advise and support people to more effectively self-manage their condition. The On@Pro platform is easily accessible and offers bite-size modules for effective and efficient continuous learning. Alongside On@Pro, we have developed other educational initiatives such as the EMEA Nurse Symposium and virtual courses for pharmacists and other healthcare stakeholders in North America. We believe that widespread education can empower healthcare professionals to help improve and simplify the lives of people living with diabetes."

"We wanted to provide an attractive and unique educational portal covering the different aspects of diabetes care relevant to healthcare professionals via a state-of-the-art platform. This tool enables personal continuous medical education that results in a CME certificate for the successful completion of the education program," concluded Prof. Dr. med. habil. Peter Schwarz, at the TUMAINI Institute. 

The modules are split into basic, advanced and add-on modules, and each one takes approximately 30 minutes to complete. The 18 basic modules cover topics relating to diabetes prevention, diabetes-related complications, diabetes in daily living and diabetes management, including nutrition and activity, self-monitoring of blood glucose, oral antidiabetic drugs, and insulin dosing. The nine advanced modules cover specific types of diabetes sub-groups or diabetes in specific scenarios – in pregnancy, in the elderly population, or in adolescents and children. They also look at accuracy in specific situations, such as low blood glucose ranges, gestational diabetes and among CGM and FGM users. Finally the four add-on modules cover e-health in diabetes, diabetes in Ramadan and blood glucose awareness training.

1. The content of the modules has been prepared by Prof. Peter Schwarz and the TUMAINI Institute and reflects their respective personal scientific views. Ascensia has no influence over the content of specific modules.
2. Certification granted by the University of Dresden and TUMAINI Institute, Germany.

 

Related Links :

https://www.ascensia.com

Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression

TOKYO, April 23, 2021 — Jolly Good Inc. ("Jolly Good") and Teijin Pharma Ltd. ("Teijin Pharma") have signed a business partnership agreement to develop VR digital therapeutics ("VR DTx") for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for depression, aiming for PMDA regulatory approval.  

Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression
Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression

Background of this agreement

This all started when Jolly Good won "Home Healthcare Award" in a program held by Teijin in Dec., 2020. Focusing of Jolly Good’s development of Cognitive Behavioral Therapy VR ("CBT VR") for psychiatric disorders, this partnership will leverage Jolly Good’s VR technology and Teijin Pharma’s expertise in knowledge and strategic skills. They have agreed that they can support healthcare workers as well as improving the quality of life of patients.

From now on, Jolly Good and Teijin Pharma will continue to develop the system and perform clinical trials to register for PMDA regulatory approval.

About Cognitive Behavioral Therapy

Cognitive Behavioral Therapy ("CBT") is a psychotherapy supporting patients to change their thoughts and behaviors by talking to a therapist. This therapy is based on the theory that your cognition on how you perceive things affects your mental and behavior pattern. CBT has been used as one of the options for non-medical treatment. 

Our developing CBT VR for depression will be used as a supplement to the actual face-to-face therapy, supporting parts such as emotional behavior or bias of perspective. Not only will it improve the effectiveness of the treatment, but it will also lessen the burden of both healthcare workers and patients.

What is a DTx division (https://vrdtx.com/en)

Jolly Good established "DTx division" in April this year, consisting of psychiatrist, regulatory specialists, and business producers familiar with VR training for people with developmental disorders. This division will focus on developing the fundamental system of digital therapeutics using VR.

DTx division will expand their pipeline to other psychiatric diseases and lifestyle diseases using the fundamental system of VR DTx. 

About Jolly Good Inc. (https://jollygood.co.jp/)

Jolly Good is a medical technology company that develops high-precision VR solutions and AI-based medical and welfare services that analyze user behavior in the VR space. Using technologies such as VR and AI, the company is accelerating human growth and social rehabilitation in medical education, support for persons with disabilities, treatment of mental illness, and so on, as well as developing services to support the evolution of medical care and finding purposes in life, in collaboration with various research institutions and companies.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan’s first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions," Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.

Please visit www.teijin.com

Soul App Motivates Gen Z to Help People Suffering from Mental Disorders, Injecting Young Energy into Social Good

SHANGHAI, March 5, 2021 — As a social networking platform that champions a genuine, diverse, and inclusive culture and stands for social good, Soul App has rolled out a series of events for the benefit of the public, especially the vulnerable, and continues to promote to its young users the values that everyone deserves respect and opportunities for personal development.

Truth be told, entrenched bias, and even stigma, lingers towards people with mental illnesses in everyday life and the workplace, considering the lack of science-based understanding of mental disorders. Ongoing public educational programs in China, which aim to narrow the information gap of mental health and call upon the general public to empathize with people suffering from mental health disorders, have imbued them with a sense of comfort and acceptance.

As part of its benevolent efforts, Soul App has lately hosted movie-watching activities featuring Pixar-produced Soul in 36 cities across China, and organized a special screening for nearly 100 children – who are living with mental health disorders including depression, cerebral palsy, and Down syndrome – and their parents and friends. Not unlike Soul which is praised as "the movie with the biggest healing power of 2020", SOUL has spread love and respect to this special group of individuals, translating into reality the uplifting theme throughout the movie of "everyone has an admirable, unique soul".

On World Mental Health Day, SOUL also held an art-for-charity exhibition named "Special Doesn’t Mean Lonely" featuring paintings created by SOUL volunteers in collaboration with teenagers on the autism spectrum. Combining aesthetic beauty and the warmth of charity, these paintings on display shined a light on their personal worlds and extraordinary artistic talents that would have gone unnoticed.

The Art-for-charity Exhibition “Special Doesn’t Mean Lonely”
The Art-for-charity Exhibition “Special Doesn’t Mean Lonely”

On December 23rd, 2020, SOUL launched their own "Different Socks Day," a philanthropic event dedicated to raising public awareness for those with special needs, encouraging people to wear two mismatched socks and to post a photo of it on the app. The campaign was such a huge success that countless young users took part in various in-app activities, such as drawing what they like on a pair of white socks, with chances of winning prizes such as tailored socks and digital gifts.

“Different Socks Day”
“Different Socks Day”

By introducing different public projects, like "Different Socks Day" and the art-for-charity exhibition, the app has tried to weave the spirit of doing good into the lives of the younger generation, empowering the belief of "committing good deeds whenever possible" to work its way into the youths’ hearts, and inspiring them to play more active roles in charitable efforts.

There has been a younger presence in socially good endeavors in recent years, and Generation Z in particular is making a noticeable and positive impact. Serving as a stronger link between philanthropic activity and the younger generation, digital platforms are playing an ever bigger role in promoting social good –with people struggling with mental disorders in mind –in more creative ways. In other words, as a rising number of young people chip in, the Gen Z-dominated social media apps, like SOUL, will emerge as a major space where amazing charitable activities happen.

Related Links :

http://www.soulapp.me

Elekta and IBA strengthen partnership to help cancer centers integrate proton therapy

Alliance pairs world-class treatment hardware and supporting software for superior proton therapy ecosystem

STOCKHOLM, March 5, 2021 — Elekta (EKTA-B.ST) announced today that its latest solution for proton therapy, Monaco®* treatment planning for protons, has received 510(k) clearance from the U.S. Food and Drug Administration. Monaco brings robust functionality for proton therapy, featuring fast optimization and calculation via the Monte Carlo algorithm and user-configurable templates for different body sites to enable rapid proton plan creation. Monaco is a component of Elekta’s Treatment Management Solution, which provides a full-featured environment for delivering proton therapy.

"Adding new technology to a department can be a complex task, and especially so for a highly advanced technique like proton therapy," says Maurits Wolleswinkel, President Linac Solutions. "In partnership with IBA, however, Elekta’s Treatment Management solution, which includes Monaco, ProKnow and MOSAIQ Plaza digital tools – including MOSAIQ Oncology Information System – provides the ideal ecosystem to integrate proton therapy, helping centers expand their capabilities to choose the best care for their patients."

Elekta was among the first companies to support proton therapy with treatment planning and oncology information systems. The company has built on this proven history to bring high quality planning, combined with intelligent, automated oncology workflows.

The partnership with IBA, a world leader in proton therapy, provides a very strong foundation with an unmatched track record of over 100,000 patients treated by IBA’s clinical partners.

"We are excited to continue expanding our successful partnership with Elekta. As proton therapy becomes an essential treatment modality for an increasing number of indications, it is critical to seamlessly integrate our solutions into the clinic and optimize workflows. Thanks to the joint in-house expertise of Elekta and IBA, and leveraging on the largest and most knowledgeable community of clinical partners in Proton Therapy, IBA is ideally positioned to complement Elekta’s integrated software solutions," says Jeroen Cammeraat, Chief Commercial Officer at IBA.

"Our ecosystem of digital tools will not only simplify and automate the oncology department, but will also enable clinicians to continuously improve, treat more patients and reduce operational costs," Wolleswinkel says.

By harnessing Elekta’s oncology informatics infrastructure, users can benefit from department-wide integration and standardized workflows. All radiotherapy machines, including linear accelerators and proton systems, will be connected, thus optimizing efficiency. This infrastructure also gives clinicians powerful analytics tools to go beyond standard efficiency improvements, using the wealth of data that the department generates to pinpoint improvements within processes. Overall, this contributes to higher productivity and cost reduction, and enables value-based healthcare.

Elekta and IBA have been collaborating for the last 20 years to help oncology centers integrate the cancer treatment modality into their patient care environment.

To learn more, visit our Proton Therapy site.

*Monaco is not available in all markets.

For further information, please contact:
Mattias Thorsson, Vice President, Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/elekta-and-iba-strengthen-partnership-to-help-cancer-centers-integrate-proton-therapy,c3300481

The following files are available for download:

Menarini Silicon Biosystems announces launch of CellMag™ product line offering affordable Gold Standard Circulating Tumor Cells capture


CELLMAG – a cost effective, manual and simple approach for the enrichment and staining of extremely rare cells from blood

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Feb. 16, 2021 — Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of its innovative CellMag product line for the manual enrichment and staining of rare circulating tumor cells (CTCs). This new product line, composed of the CellMag CTC Epithelial Cell kit, a magnetic tool and consumables, will allow all liquid biopsy and CTCs Laboratories to have access to a manual system using the same ferrofluid technology offered by the Gold Standard CELLSEARCH system.

This easy to use technology offers researchers who work on translational projects a reliable tool to study the heterogeneous biology of CTCs, whose presence in blood has been associated with poor prognosis in metastatic carcinomas[1].

Despite different available methods to capture CTCs, only the information obtained from CTCs that have been captured by the CELLSEARCH ferrofluid technology have shown a robust clinical value in different settings[1]. Research laboratories will appreciate the convenience, simplicity and affordability of CellMag. Researchers can analyze and characterize enriched CTCs from a molecular perspective with a high level of specificity, gaining valuable insights into how certain tumors progress and disseminate throughout the body. "CellMag is a manual system for the capture and enhancement of CTCs using the established ferrofluid technology. Perfectly tailored to our research needs, it offers a manual version of the reference CELLSEARCH platform," said Dr. Catherine Alix-Panabières, Associate Professor and Director of the Laboratory of Rare Human Circulating Cells (LCCRH) at the University Medical Center of Montpellier, France.

The CellMag CTC Ephitelial Cell kit allows research centers, focusing on liquid biopsies, to conduct highly specific, established and standardized immunomagnetic enrichment and staining of CTCs in peripheral blood. Following the positive selection of enriched cells, performed by capturing cells through ferrofluids labeled with antibodies that target the (EpCAM) antigen, the staining procedure delivers cells that are ready for enumeration, isolation and downstream analysis. The final step of cell sorting can be performed by the DEPArray system or other downstream applications including flow cytometry, fluorescent microscopy or molecular and phenotype analyses.

For Fabio Piazzalunga, President and CEO of Menarini Silicon Biosystems: "Our manual CellMag product line allows all liquid biopsy and CTCs Laboratories to reach high specificity in cell enrichment and staining, leveraging the established CELLSEARCH ferrofluid technology. With this simple and standardized solution we are committed to helping all researchers develop scientific understanding and improve medical knowledge related to human diseases." 

The CellMag product line family will be expanded in the coming months to offer a series of additional kits for the enrichment of other rare cell types.

About CELLMAG™

CELLMAG is intended for Research Use Only (RUO) – not for use in diagnostic procedures. This product line allows for highly specific and standardized cell enrichment and staining. Cells captured with the CellMag technology are comparable to those captured with the CELLTRACKS® AUTOPREP® System. The product line is composed of an epithelial CTC kit, for ferrofluid-based EpCAM positive CTC enrichment, a magnetic tool and consumables. The process involves a sample preparation phase, followed by the magnetic separation of CTCs, sample washing, permeabilization and staining.

For more information on the CELLMAG product line, please refer to www.siliconbiosystems.com/cellmag

About Menarini Silicon Biosystems

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization.

Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.

Reference

[1] Riethdorf S, O’Flaherty L, Hille C, Pantel K. Clinical applications of the CellSearch platform in cancer patients. Adv Drug Deliv Rev. 2018 Feb 1;125:102-121. doi: 10.1016/j.addr.2018.01.011. Epub 2018 Feb 2. PMID: 29355669.

Contact:
Linda Pavy
linda.pavy@bcw-global.com

 

Related Links :

http://www.siliconbiosystems.com/

Safer medical devices with Picosun’s antimicrobial ALD coatings

ESPOO, Finland, Feb. 13, 2021 — Picosun Group, the leading provider of AGILE ALD® (Atomic Layer Deposition) thin film coating technology and solutions, reports excellent aseptic properties measured from its ALD materials.

Numerous ALD oxide coatings deposited with Picosun’s processes showed remarkable reduction of microbial growth and had low values of bacterial endotoxin contamination(*). The coatings were characterized by an independent third party laboratory according to ISO 22196:2011 antimicrobial standard and ANSI/AAMI ST72:2019 bacterial endotoxin standards. These results, along with the earlier tests validating the non-cytotoxicity of Picosun’s ALD films, prove the safety and aseptic benefits of these materials in medical devices, both implanted and external ones.

Millions of people worldwide live with medical implants and the trend is towards even more complex solutions that combine highly advanced microelectronics with miniaturized devices embedded into sensitive areas of the body such as brain, spine, eyes, and heart. Protecting these devices from the corrosive environment of the human body, and vice versa, is of utmost importance considering the safety, correct operation, and lifetime of the implant.

Picosun is the trailblazer in providing medical ALD solutions to device manufacturers. Picosun’s ultra-thin, biocompatible ALD coatings guarantee hermetic encapsulation of the implanted device, with a fraction of film thickness compared to other coating methods and with superior film uniformity and conformality, ensuring pinhole-free coverage over even the smallest details of the device. Extended lifetime and operational reliability of the implant reduces the need for corrective or replacement surgeries, thus saving expensive hospital stays and improving the patient’s quality of life. For manufacturers, hermetic protective coating enables use of more common base materials, e.g. stainless steels instead of precious metals, which in turn makes the manufacturing process easier and saves costs.

"The aseptic properties of our ALD films are so excellent that they surpass even the strictest requirements of the medical implant industry. We are excited to bring our new, advanced medical ALD solutions to the market and help our customers keep spearheading their industries with safer, longer-lasting and user-friendly products," states Juhani Taskinen, Head of Medical Business Area of Picosun Group.

Picosun provides the most advanced AGILE ALD® (Atomic Layer Deposition) thin film coating solutions for global industries. Picosun’s ALD solutions enable technological leap into the future, with turn-key production processes and unmatched, pioneering expertise in the field – dating back to the invention of the technology itself. Today, PICOSUN® ALD equipment are in daily manufacturing use in numerous leading industries around the world. Picosun is based in Finland, with subsidiaries in Germany, USA, Singapore, Japan, South Korea, China mainland and Taiwan, offices in India and France, and a world-wide sales and support network. Visit www.picosun.com.

(*)The results are part of ULIMPIA project, funded by PENTA under grant number PENTA-2017-Call2-16101-ULIMPIA.

More information:
Mr. Juhani Taskinen
Head of Medical Business Area, Picosun Group
Tel: +358 50 4066 957
Email: info@picosun.com
Web: www.picosun.com
 

CONTACT:

Minna Toivola
D.Sc., Marketing Manager, Picosun Oy
Email: minna.toivola@picosun.com
Tel: +358 40 758 8748

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/picosun-oy/r/safer-medical-devices-with-picosun-s-antimicrobial-ald-coatings,c3285079

The following files are available for download:

https://mb.cision.com/Main/16058/3285079/1371655.pdf

Safer medical devices with Picosun’s antimicrobial ALD coatings